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ABSTRACT
Objectives: This article describes the framework of a
comprehensive European model developed to assess clin-
ical and economic outcomes of cardiac resynchronization
therapy (CRT) versus optimal pharmacological therapy
(OPT) alone in patients with heart failure.
Methods: The model structure is based on information
obtained from the literature, expert opinion, and a Euro-
pean CRT Steering Committee. The decision-analysis tool
allows a consideration of direct medical and indirect
costs, and computes outcomes for distinctive periods of
time up to 5 years. Qualitative data can also be entered
for cost-utility analysis. Model input data for a prelimi-
nary economic appraisal of the economic value of CRT in
Germany were obtained from clinical trials, experts,
health statistics, and medical tariff lists.
Results: The model offers comprehensive analysis capa-
bilities and high ﬂexibility so that it can easily be adapted
to any European country or special setting. The illustra-
tive analysis for Germany indicates that CRT is a cost-
effective intervention. Although CRT is associated with
average direct medical net costs of €5880 per patient, this
ﬁnding means that 22% of its upfront implantation cost is
recouped already within 1 year because of signiﬁcantly
decreased hospitalizations. With €36,600 the incremental
cost per quality-adjusted life-year (QALY) gained is below
the euro equivalent (€41,300, €1 = $US1.21) of the com-
monly used  threshold  level  of  $US50,000  considered
to represent cost-effectiveness. The sensitivity analysis
showed these preliminary results to be fairly robust
towards changes in key assumptions.
Conclusions: The European CRT model is an important
tool  to  assess  the  economic  value  of  CRT  in  patients
with moderate to severe heart failure. In the light of the
planned introduction of Diagnosis Related Group (DRG)
based reimbursement in various European countries, the
economic data generated by the model can play an impor-
tant role in the decision-making process.
Keywords: biventricular pacing, cardiac resynchroniza-
tion therapy, cost-effectiveness, CRT, economic, heart
failure, model.
Introduction
Heart failure (HF) is a major public health problem
in developed countries. In Europe, an estimated 1%
to 2% of the general population is affected by HF
with a rapid increase in the prevalence for the older
age groups [1,2]. HF is associated with a substantial
morbidity and mortality risk with reported death
rates as high as 40% within 1 year of initial diag-
nosis [3–6]. In Germany, approximately 1.3 million
people suffer from this disease, and the incidence is
estimated at 200,000 patients per year [7]. There is
evidence too that the occurrence of HF will dramat-
ically increase in the future mainly because of the
aging of the population [1].
HF represents the leading cause of hospitaliza-
tion in persons aged 65 years and older [8]. Around
50% of patients who are hospitalized require recur-
rent admissions for periods of decompensation of
the HF syndrome within the ﬁrst 3 months after
hospital discharge [9]. As a result of this, HF
accounts for as much as 1% to 2% of total health-
care costs [10,11]. Approximately two-thirds of
these costs are caused by hospitalization [12]. It is
also known that treatment costs increase with the
severity of HF. Moderate to severe (New York
Heart Association [NYHA] class III–IV) HF
patients is estimated to comprise 35% to 45% of
the total HF population [3,13].
Through the implementation of more effective
pharmacological regimens remarkable improve-
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ments in clinical outcomes were achieved along
with reductions in the morbidity and mortality of
patients with HF [14–17]. Despite these pharmaco-
logical advances, however, HF remains a disease
with unacceptably high mortality rates, frequent
hospital admissions, and poor quality of life [3].
Surgical therapies such as heart transplantation are
unquestionably of great value but are limited by the
shortage of donor organs, and left ventricular (LV)
assist devices are implanted in relatively few cases
because of restrictions.
Recently, cardiac resynchronization therapy
(CRT—or  biventricular  pacing)  has  emerged  as
an effective treatment for patients with advanced
HF and intraventricular conduction delay who are
refractory to medical therapy. This condition is
present in up to 30% of patients with chronic HF
[18]. In contrast to traditional right ventricular pac-
ing, cardiac resynchronization uses an LV lead that
is usually positioned in the coronary vein. The CRT
system ensures a synchronized activation of the left
and right ventricle with the result of enhanced car-
diac function and reduced myocardial oxygen con-
sumption. In numerous studies CRT implantation
was followed by a signiﬁcant reduction in HF-
related hospitalization and remarkable impro-
vements in the NYHA functional classes and the
quality of life [19–23]. A recent meta-analysis dem-
onstrated that CRT is capable of reducing death
from progressive HF within a 3- to 6-month follow-
up period, whereas all cause mortality also declined
although not reaching a statistically signiﬁcant level
[24]. Information on the overall durability of CRT
is limited to date although because this technology
was introduced into clinical practice only recently.
Yet most actual data from the Comparison of Med-
ical Therapy, Pacing, and Deﬁbrillation in HF trial
(COMPANION, Bristow MR et al., [23]) indicates
that the device appears to properly work for periods
of at least 3 years.
Although there is clinical evidence in terms of
CRT effectiveness, questions surrounding its cost-
effectiveness are raised. This issue gains in impor-
tance as cost-containment measures are increasingly
implemented in health care to control the steadily
rising medical expenditures. Given the limited med-
ical resources, health-care providers and third-party
payers thus not only focus on the quality of care
alone but also on the economic consequences of
interventions.
The major problem to a further adoption of CRT
at this point thus appears to arise from economic
considerations rather than from concerns about its
medical usefulness. As hospitalization costs repre-
sent the cost driver in HF management, the remark-
able decline in the number of hospital days
subsequent to implantation of a biventricular pac-
ing system implies major cost savings down the
road when compared with optimal pharmacological
therapy (OPT) alone. Because most CRT costs are
high and upfront resulting from the implantation
costs, the key question arises whether these costs
can be offset by postinterventional savings in inpa-
tient care over time. Quality-of-life also should be
addressed in an economic evaluation because this
aspect represents an important beneﬁt for the
patient.
For the assessment of the economic performance
of CRT, we developed a comprehensive European
decision-analytic model designed to compare the
incremental clinical and economic effects of CRT
(plus OPT) with those of OPT alone. With the use
of our model crucial information on the cost-
effectiveness of CRT can be generated which serve
to provide decision makers in health care with
essential data on the value for money of this new
medical technology.
This article concentrates on a detailed descrip-
tion of the model framework, the economic out-
comes generated by the software, and an appraisal
of the probable cost-utility ratio of CRT in Ger-
many based on the information available to date.
The software can also be used to compute data for
an assessment of the cost impact of CRT on health-
care systems.
Methods
Decision Analytic Model
Based  on  information  obtained  from  a  review  of
the published key literature containing information
on the management and clinical outcomes of HF
patients, we developed a ﬁrst draft of the model
framework. To assure that the structure of the
model captures all important clinical aspects and
essential outcomes of the two compared therapeutic
strategies, the model concept was presented to and
reﬁned by nine European medical experts with
whom individual face-to-face interviews were con-
ducted. These interviewed physicians included CRT
implanters, experts for the inpatient care of HF
patients, and HF specialists working in the ambu-
latory setting. Additionally, the established Euco-
med CRT Steering Committee was also involved in
the validation of the model framework. Main
objective was to develop a comprehensive and user-
friendly European core model to compare the clin-
ical and economic effects of a CRT treated cohort
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with that of a cohort treated with OPT alone. In
accordance with routine medical practice, the
model takes into account that patients undergoing
CRT are concomitantly treated with OPT. Because
of its ﬂexibility the model can easily be adapted to
any clinical setting, thus offering a tool for eco-
nomic analyses applying to different European
countries or speciﬁc settings. Table 1 provides a
summary of the model input variables. It has to be
pointed out, however, that the input data demanded
by the model depend on the selected economic per-
spective (payer, societal).
An additional advantage is that the model
approach offers an efﬁcient method of quickly pro-
ducing updated results once new information from
future CRT trials, registries, or meta-analyses
become available. The software is designed to com-
pute acute  and  longer-term  results  for  the  follow-
ing distinctive analysis time points: 6 months,
12 months, 18 months, and for years 2, 3, 4, and 5.
The front end of CRT model is programmed in
Microsoft Visual Basic and is connected to a Micro-
soft Access database and an export interface to
Excel for the presentation of detailed results.
Model Framework
Figure 1 depicts the clinical structure of the CRT
model which incorporates a submodel to assess the
Table 1 Overview of  the entire model input data set (full list)
Epidemiological data
• Total population in the analyzed country
• Prevalence of  heart failure
• Proportion of  patients suffering from moderate to severe heart failure (NYHA class III/IV)
—of these: percentage of  patients meeting criteria for CRT implantation
—of these: percentage of  patients actually treated with CRT
Clinical data
For CRT group only:
• Percentage of  patients with successful LV lead implantation
• Peri-operative mortality in percent
• Probabilities of  complications associated with the CRT procedure (dissection/perforation, lead dislodgment, pneumo-/hemothorax, cardiac 
tamponade, phrenic nerve stimulation, device-related infection, other type of  complication)
For both groups (individual values for the different follow-up time points):
• Probability of  hospital admission during the follow-up period
• Probability of  death during the follow-up period
• If  available: percentage of  patients undergoing a procedure during their hospitalization (radiofrequency ablation, heart transplantation, CABG, 
PTCA/Stent, ICD, or another procedure)
• Drug treatment in terms of  the percentage of  prescribed drug classes (diuretics, spironolactone, cardiac glycosides, ACE inhibitors, angiotensin 
II blockers, beta-blockers, aspirin, anticoagulants, calcium antagonists, antiarrhythmics, other drugs)
Information on NYHA class and utilities
• Percentage of  patients in the different NYHA classes at baseline and during the follow-up (for both groups separately)
• Utility values for each of  the four NYHA classes
Economic information
For CRT group only:
• Total system price or average number of  units of  material used per patient for the CRT procedure (CRT device, right atrial lead, right ventricular 
lead, left ventricular lead, delivery system, other disposables) and the unit cost for these materials
• Cost of  drugs used during the intervention (contrast media, anesthetic drugs)
• Cost of  the personnel involved in the CRT implantation procedure (implanters, nurses)
• Cost of  the use of  the operation room or the catheterization laboratory
• Average length of  hospital stay associated with the CRT implantation (differentiated between ICU and or the cardiology ward) and unit costs 
for the two wards
• Incremental cost of  an implant failure
• Incremental cost of  death
• Incremental cost of  each of  the potential complications
For both groups:
• Average monthly drug treatment cost for each of  the drug classes considered
• Mean number of  day hospitalizations/hospitalized patient (for the different time periods)
• Mean number of  hospitalizations/hospitalized patient (for the different time periods)
• Average total length of  stay per hospitalization
• The relative proportion (in percent) of  ICU stay relative to the total hospital stay
• Unit cost of  day hospitalization, and the daily rate of  stay in the ICU and the normal cardiology ward
• DRGs for the possible procedures performed during the hospitalization
• Average yearly number of  routine outpatient physician services per patient and corresponding unit costs
• Average yearly number of  professional home care visits per patient and unit cost
For the valuation of  productivity losses, the following estimates are required:
• Percentage of  patients still employed at baseline
• Proportion of  patients with temporary work loss per year (for both groups)
• Mean number of  work days lost per patient and year (for both groups)
• Cost per work day lost
• Average age of  the patient population and the pension age
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short-term outcomes (ﬁrst 30 days) of the index
CRT implantation and a second submodel to assess
the long-term follow-up outcomes for the two com-
pared treatment groups (CRT + OPT, OPT alone).
The model assumes that the CRT procedure can
be successful (successful LV lead implant) with an
estimated event rate of 92.5% assumed for our Ger-
man appraisal [19], or fail (unsuccessful LV lead
implant), estimated to occur in 7.2% of attempted
implantations. These latter cases are deﬁned as
mainly those with unsuccessful coronary sinus cath-
eterization, unsuccessful lead progression into the
coronary sinus, or unstable positioning of the LV
lead. Regarding clinical outcome algorithms
implant failures are treated like OPT alone patients,
but outcomes are allocated to the CRT group
(intention-to-treat approach). Finally, 0.3% of
patients are assumed to die from the intervention
because of serious peri-procedural complications
(procedural death) [19].
Most of the patients undergoing implantation of
a CRT system do not experience any clinically rel-
evant complication (no complication). The remain-
ders with adverse events (complication) may
experience coronary sinus dissection or perforation
(assumed incidence of 0.5%) [19], early dislodg-
ment of leads (0.7%) [19], pneumo- or hemotho-
rax (1%, based on expert estimates), cardiac
tamponade (0.9%) [25], phrenic nerve stimulation
(1.3%) [26], and device-related infection (1.3%)
[19].
The structure of the follow-up submodel applies
to both treatment groups. Patients surviving a spe-
ciﬁc analysis cycle re-enter the same submodel for
the subsequent cycle calculation (cycle time points:
months 6, 12, 18, 24, 36, 48, and 60). What differs
between the two compared groups as well as within
a group over time are the probabilities of the ana-
lyzed clinical outcomes. As displayed in Figure 1,
patients entering the follow-up submodel can expe-
rience three main outcomes: they can ﬂow into the
health state “no hospitalization” which deﬁnes a
patient who is well controlled and thus does not
require any HF-related hospitalization within a
Figure 1 Framework of  the decision analytic model designed to compare the clinical and economic effects of  CRT (plus OPT) versus OPT alone
over distinctive periods of  time (up to 5 years). CABG, coronary artery bypass graft; CRT, cardiac resynchronization therapy; ICD, implantable car-
dioverter deﬁbrillator; LV, left ventricular; OPT, optimal pharmacological therapy; PTCA, percutaneous transluminal coronary angioplasty; , deci-
sion node; , chance node; , node deﬁning surviving patients who enter next analysis cycle (re-enter calculation for next cycle at state
“Survivors”); , terminal node.
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given analysis cycle.  The  second  possible  outcome
is “hospitalization” and the third possibility is that
the patient dies (health state “death”) mostly be-
cause of progressive HF.
The follow-up model framework also allows
consideration of eventual interventional or surgical
procedures conducted during the hospital stay.
Main procedures include: radiofrequency ablation,
CRT revision (only for CRT group and up to an
assessment period of 6 months), intervention for
device-related infection (e.g., explantation of pacing
system—only for CRT group and up to an assess-
ment period of 6 months), heart transplantation,
coronary artery bypass graft (CABG), percutaneous
transluminal coronary angioplasty or stent implan-
tation (PTCA/Stent), or implantation of a cardio-
verter deﬁbrillator (ICD). The probability of the
health state “without procedure” is computed as 1
minus the sum of the probabilities of the various
procedures. It represents a health state where the
patient is hospitalized but treated only conserva-
tively, that is, not undergoing a percutaneous or sur-
gical intervention.
Data Sources
Clinical Data
Because of data availability in view of the relatively
new CRT technology, clinical information required
to “feed” the model was collected from various
sources. These included the published literature,
health statistics, and expert opinion. For the reason
of reliability, highest priority was given to rand-
omized comparative trials. To capture pertinent
information on HF management in general and clin-
ical outcomes associated with CRT and OPT alone
in patients with advanced HF in particular, a com-
prehensive review of the published study literature
was carried out. All relevant information was
assembled in the format of a literature synthesis. To
obtain complementary information on the clinical
effects of the compared therapeutic approaches and
their corresponding treatment algorithms, face-to-
face interviews with nine medical experts in various
European countries were carried out. These special-
ists were selected in terms of their experience as
regards CRT implantation, and the general manage-
ment of patients with HF.
Economic Data
The above described data collection also served to
identify and pull together relevant economic infor-
mation, on a country-speciﬁc basis if feasible,
needed for the illustrative German model appraisal.
Moreover, country-speciﬁc statistics were screened
to identify potentially relevant epidemiological and
resource use data (e.g., length of hospital stay for
admissions related to HF). Lastly, substantial efforts
were undertaken to re-analyze existing trials and
registries to retrieve country-speciﬁc key economic
data (e.g., length of stay for CRT patients and
patients treated with OPT alone, rate of hospital
readmissions, frequency of ambulatory physician
follow-up visits).
Qualitative Data (quality-adjusted life-years)
The comprehensive model allows considering
changes in the NYHA classiﬁcation occurring over
time in the two treatment groups by means of an
estimation of the proportion of patients allocated to
each of the four NYHA classes (NYHA class I–IV).
At baseline, we assumed that both compared treat-
ment groups have an identical distribution (90% of
patients in NYHA class III, 10% of patients in
NYHA class IV, resulting in an average NYHA class
score of 3.1). This assumption is comparable to that
of two recently published randomized CRT trials
[19,23]. For the follow-up periods (at 6 months and
12 months) we assumed that the average NYHA
class score will improve in the CRT group to a value
of 2.1 based on consistent ﬁndings reported in var-
ious studies [19,27–29]. As concerns the group
treated with OPT alone, it was assumed that no
such improvement will occur because these patients
are already receiving the most efﬁcient pharmaco-
logical therapy. The corresponding proportional
distribution among the different NYHA categories
at baseline and the follow-up time points for the
two compared treatment groups is shown in the
lower part of Table 2.
The model further allows allocating an individ-
ual health utility value to each of the four different
NYHA classes which are displayed in Table 2.
These health utilities represent a measure of the
quality of life. In this approach any state of illness
or disability may be assigned a utility on a scale
from 0 to 1, where a value of 1 represents perfect
health and a value of 0 represents death. The health
utility values used in our model are taken from the
only published investigation to our knowledge that
provides health utility values for each of the four
functional classes [30]. By taking into account the
death rate and the NYHA distribution at the differ-
ent analysis time points as well as the utility values,
the model can calculate the cumulative number of
quality-adjusted life-years (QALYs) for two treat-
ment cohorts. With this information, computation
of the incremental cost per QALY gained (cost-
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utility ratio) is possible. The general formula for this
calculation is:
Clinical Model Input Data
The upper part of Table 2 summarizes the key
assumptions made regarding the clinical base case
data used as input for the illustrative German anal-
ysis. Displayed are the probabilities of the various
short-term clinical events after CRT implantation
(up to 1 month) and the longer-term outcomes for
both treatment groups for the analysis time periods
of 6 and 12 months. These probabilities are applied
to the corresponding health outcomes considered in
the model (Fig. 1).
Assumptions for drug usage is primarily derived
from trials and complemented by expert opinion
Cost-utility
 ratio =
Cost of treatment B – Cost of treatment A
No. of QALYs generated by treatment B
– No. of QALYs generated by treatment A
where published data were either unavailable or
heterogeneous. Table 3 shows the percentage of
patients treated with the different classes of HF
medications and the sources of information.
Table 2 Model input data used for the German illustrative example. Note that the displayed data represent cumulative values.
Also shown are the utility values assigned to the four NYHA classes together with the proportional distribution of  patients among
the four NYHA classes for the two groups
Incidence of  clinical outcomes M0–1 M0–6 M0–12 Source
Short-term outcomes CRT implantation (%)
Successful LV lead implantation 92.5 [19]
Unsuccessful LV lead implantation 7.2 Calculated (100 – 92.5 – 0.3)
Procedural death 0.3 [19]
Of patients with successful implantation
Lead dislodgment 0.7 [19]
Coronary sinus dissection/perforation* 0.5 [19]
Pneumo-/Hemothorax 1.0 Expert estimate
Cardiac tamponade 0.9 [25]
Phrenic nerve stimulation 1.3 [26]
Long-term outcomes (%)
OPT alone M0–6 M0–12
Death (all causes) 6.3 19.0 [19] [23]
Hospitalization (due to HF) 15.1 25.0 [19] Derived from [1]
Heart transplantation 0.9 4.0 [19] Own assumption
CRT + OPT
Death (all causes) 4.9 15.0 [19] [2]
Hospitalization (due to HF) 7.9 13.0 [19] Ratio from OPT alone
CRT revision (due to lead dislodgment) 5.2 NA [19]
Device-related infection 1.3 NA [19]
Heart transplantation 0.0 3.0 [19] [29]
Utilities Utility value
NYHA class IV 0.30 [30]
NYHA class III 0.65 [30]
NYHA class II 0.80 [30]
NYHA class I 0.97 [30]
Distribution among the 4 NYHA classes (%) Baseline M0–6 M7–12
NYHA class 1—OPT alone 0 0 0 Based on [19,27–29]
NYHA class 2—OPT alone 0 0 0 Based on [19,27–29]
NYHA class 3—OPT alone 90 90 90 Based on [19,27–29]
NYHA class 4—OPT alone 10 10 10 Based on [19,27–29]
NYHA class 1—CRT + OPT 0 20 20 Based on [19,27–29]
NYHA class 2—CRT + OPT 0 55 55 Based on [19,27–29]
NYHA class 3—CRT + OPT 90 20 20 Based on [19,27–29]
NYHA class 4—CRT + OPT 10 5 5 Based on [19,27–29]
*Cases requiring a therapeutic intervention because of  the event.
M, denotes month (e.g., M0–6 represents the follow-up period between baseline and month 6); NA, not applicable to time frames > 6 months because these events
occur only in the shorter term.
Table 3 Drug treatment regimens for the two compared
groups
Drug class
% of  use 
Source
OPT
alone
CRT +
OPT
Diuretics 94 94 [19,22,29]
Spironolactone 65 65 Expert estimate
Cardiac glycosides 78 78 [19]
ACE inhibitors 75 75 [27–29]
Angiotensin II blockers 15 15 [27,29]
Beta-blockers 55 80 [19,20,27, expert
estimate]
Aspirin 85 85 Expert estimate
Anticoagulants 35 35 [27,29]
Calcium antagonists 15 15 [29]
Antiarrhythmic drugs 50 50 [27,29]
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Model Outcome Data
The model algorithms allow computing the direct
medical, indirect, and total costs per treatment
group and the average costs per patient along with
the corresponding incremental net costs or savings
of CRT implantation as compared with OPT alone.
In terms of cost-utility, the model computes the
incremental cost per QALY gained.
For  the  validation  of  the  economic  part of
the model, data from the Brescia study [27] were
entered into the model to compare the out-
comes generated by the model with that reported
in the article. The difference in the economic
ﬁndings was minor, which proves the model to
be valid.
Possible Analytic Perspectives
The model allows the computation of economic
results for the perspective of the payer and that of
the society. The payer perspective focuses on the
costs (charges) associated with the direct medical
resource utilization. Goods and services taken into
account in terms of direct costs comprise: the CRT
procedure (only applies to CRT group), hospital
care based on Diagnosis Related Group tariffs
(DRGs) or on per diem charges depending on the
reimbursement system, outpatient physician follow-
up care, drug treatment, and diagnostic examina-
tions. Eventual patient copayments for prescribed
drugs and/or hospitalization are subtracted from
the full unit costs because these amounts are not
covered by the payer. The societal perspective
includes the direct medical resource utilization
described above but additionally also eventual pro-
ductivity losses attributable to the disease in the per-
centage of the population that is still gainfully
employed. The model can take into account work
loss due to temporary morbidity but also due to pre-
mature death.
Illustrative Economic Analysis for Germany
The perspective adopted for the German appraisal
is that of the third-party payer, that is, the sickness
funds. All cost values are based on ﬁnancial year
2002. Because most CRT study results are conﬁned
to a follow-up period of 6–12 months, the evalua-
tion presented here covers an analysis time period of
1 year. This implies that costs considered in this
analysis are not discounted because they all accrue
within 1 year. In the light of the data uncertainties,
sensitivity analysis was performed to investigate the
impact of varying input values assigned to crucial
model variables on the ﬁnal outcome.
Cost-Assessment Approach and Economic 
Model Input Data
For the estimation of treatment costs, the amount of
medical resources used from baseline up to the end
of the 1-year analysis period were multiplied with
the corresponding unit cost. The assumed cost of
the CRT implantation procedure was derived from
average selling prices of all relevant material used
for this procedure (manufacturer information), with
addition of the cost estimated for the personnel
involved in the implantation and the use of the
operation room, as well as the cost for an assumed
procedure-related average length of stay in the
normal cardiology ward of 2 days (uncomplicated
case). For the event of a failed implantation we
assumed that the procedure would prematurely be
interrupted after unsuccessful attempts to position
the LV ventricular lead, without subsequent referral
of the patient to surgery. This implies that the cost
of a failure is less than the cost of a successful
implantation because some of the material—espe-
cially the CRT device itself—is not used. The incre-
mental costs assigned to other complications of the
CRT procedure are estimated based on the percent-
age of patients requiring therapeutic interventions
and the prolongation of hospital stay, as indicated
by the interviewed experts. The costs assigned to
hospitalization associated with the index CRT pro-
cedure or readmissions during the follow-up period
are based on an average daily rate, with differenti-
ation between days in the normal cardiology ward
or the intensive care unit [31], or on a lump-sum fee
where applicable. The cost of routine outpatient fol-
low-up care considers the average number and type
of routine service rendered to a patient per year val-
ued by means of the ofﬁcial medical tariff list (this
list reports tax points) [32]. These tax points were
then multiplied with an assumed tax point value of
euro 0.036. The cost of medication reﬂects the
pharmacy sales price as speciﬁed in the German
drug compendium [33]. Table 4 assembles the eco-
nomic parameters and their unit costs used for the
analysis. Death during the follow-up period was
assigned a cost value of zero because there were no
German-speciﬁc data available.
Sensitivity Analysis
Key assumptions for the model were explored by
means of sensitivity analysis. A best and worst case
scenario was conducted by making assumptions on
values of most sensitive model parameters that are
superior or inferior to the base case assumptions,
respectively. These most sensitive parameters
include the length of hospital stay, the unit cost per
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hospital day, the reduction in the probability of hos-
pitalization after CRT, the CRT implantation cost,
and the distribution of patients into the different
NYHA classes. The worst case scenario is therefore
based on assumptions that imply decreased clinical
and economic beneﬁts of CRT: a smaller reduction
in the average length of hospital stay for a CRT
patient relative to an OPT patient of only 40% (9.3
vs. 15.5 days; base case assumption: 55%), a 20%
lower unit cost each for an ICU and a cardiology
ward day reﬂecting charges of a mid-sized hospital
(€750 and €270, respectively), no change from the
base case value for the reduction of hospital admis-
sions in the CRT group because MIRACLE already
shows a conservative ﬁnding when compared with
other studies [21,27,34], an 10% increased cost of
the CRT procedure (€8250 vs. €7500 including the
index hospital stay) as the base case value reﬂects an
estimate, and an assumed post-CRT improvement
in the average NYHA class of only 0.8 (from 3.1 to
2.3; baseline assumption: 3.1 to 2.1). The best case
scenario takes into account a higher reduction in the
average length of hospital stay per admission for a
CRT patient relative to an OPT patient of 77%
(assumption: 3.5 vs. 15.5 days) as reported in a
recent analysis [34], a 20% higher unit cost each for
an ICU and a cardiology ward day reﬂecting
charges applicable to a university hospital (€1130
and €410, respectively), a reduction of hospital
admissions related to CRT implantation of 80%
(base case value 48%) as observed in three econom-
ically oriented studies [21,27,34], a 10% decreased
cost of the CRT procedure (€6750 including the
associated hospital stay), and an improvement in
the average NYHA class by 1.2 (from 3.1 to 1.9 as
reported in the PATH-CHF trial).
Results
Table 5 summarizes the main preliminary outcomes
when taking into account the assumed base case
input data described in Tables 2 and 4. In terms of
clinical effects, the model predicts that biventricular
pacing reduces the number of hospital days by
71%, and leads to a decrease in the risk of death by
18%.
Economically, the CRT implantation results in
average per-patient net costs of €5880 by the end of
the ﬁrst year after the procedure. This means that
22% of the upfront costs of the procedure can be
offset already within 1 year because of the favorable
effect on the frequency of hospital readmissions.
From the viewpoint of the cost-utility of CRT, the
resulting cost per QALY gained of €36,600 is below
the current equivalent in euros of the commonly
used threshold values of $US50,000 or English
£30,000 considered as level up to which a treatment
is judged as cost-effective [35].
The sensitivity analysis shows that these base
case ﬁndings are rather robust with regard to the
model’s assumptions. As a result of the worst-case
scenario, the net incremental cost of CRT rises to an
amount of €6920, whereas the incremental cost per
QALY gained is €52,100. This ratio is somewhat
Table 4 Economic parameters and unit costs used for the preliminary model analysis for Germany
Economic parameters OPT alone CRT + OPT Source
Hospitalization
Mean number of  hospitalizations/hospitalized patient 1.5 1.4 Projected from [19]; SA
Average length of  stay (days) per hospital admission 15.5 7.0 [2] for OPT group; proportional value
for CRT group projected from [19]
Percentage of  ICU stay relative to total hospital stay 7% 5% Derived from [27]
Unit cost
Drug treatment (per year) €780 €815 Based on prescription schedule and [33]
Follow-up outpatient management (per year) €360 €455 Based on physician services and [32]
General unit costs
CRT procedure (including hospital stay) €7,500 Derived from manufacturer information
and implanters
Implant failure €2,300 Based on expert data
Peri-procedural death — No data available
Heart transplantation €36,500 DRG value
Per diem rate ICU €940 [31]
Per diem rate normal ward €340 [31]
Incremental cost of  complications (per event)
Dissection/Perforation €340 Based on expert data
Lead dislodgment/CRT revision €1,800 Based on expert data
Pneumo-/Hemothorax €2,400 Based on expert data
Cardiac tamponade €2,400 Based on expert data
Phrenic nerve stimulation €190 Based on expert data
Device-related infection €6,800 Based on expert data
SA, special analysis German CHF.DE Registry.
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higher than the current euro equivalent of the above
mentioned threshold levels in $US or English £ but
still lower than that of other well accepted health
interventions. When analyzing the best-case sce-
nario, the  net  cost  of  CRT  after  1 year  decreases
to €4600 which is equivalent to 32% recouped
upfront costs. The incremental cost per QALY
gained also improves to €22,400.
Discussion
As health-care resources become more limited, out-
come measures have gained increasing importance.
In an effort to maintain high quality care despite
limited medical resources health-care providers
become more focused on cost efﬁciency than just on
quality of care alone. Cost-effectiveness arguments
are therefore playing a more prominent role in the
decision-making process. One tool for the cost-
utility measurement of medical technologies is the
concept of QALYs. Already widely used in the
United States, this concept is also beginning to
spread in Europe. In England for instance the
National Institute of Clinical Excellence (NICE)
demands QALY data for its process of appraisal.
To generate crucial data for a reliable assessment
of the economic performance of CRT in the man-
agement of patients with moderate to severe HF and
conduction delay, a comprehensive European deci-
sion analytic model was developed, which allows
assessing the overall cost of treatment over time
along with computation of the cost-utility ratio.
The model compares patients undergoing CRT
implantation (plus OPT) with those treated conven-
tionally with OPT alone. This article describes the
framework of this simulation tool and its input and
output variables. A main asset of the model is its
ﬂexibility in terms of the detailed data that can be
entered for an evaluation, which makes it suitable
for the analysis of basically any speciﬁc scenario.
This is particularly important because the model is
designed  for  use  in  different  countries  as  well  as
for performing efﬁcient result updates once new key
information from future CRT trials become availa-
ble. With the integrated epidemiological module,
the software can also be used for cost-of-illness
analyses in HF and cost impact appraisals.
To our knowledge there is one other published
article available that contains information about an
economic HF model developed for a similar pur-
pose as ours [36]. In contrast to our model, this
Canadian  model  focuses  on  a  limited  comparison
of the follow-up care costs of OPT patients versus
patients undergoing an intervention with a new
technology such as CRT but does not consider the
eventual short-term outcomes complications and
the cost of such an intervention. The basic model
framework of the Canadian and our model as con-
cerns the follow-up period, however, is similar (with
consideration of three health states: “Managed,”
“Complicated,” that is, patients with a hospital
admission, and “Death”). A comparison of
economic outcomes is complicated, although, as
assumptions regarding clinical outcomes and esti-
mates of unit costs used for the calculation, when
applying the current exchange rate of €1.66 to
$Can, vary substantially. When excluding the over-
all cost of CRT implantation in our analysis, both
evaluations provide evidence of a substantial reduc-
tion in follow-up care costs attributable to CRT
implantation yet, resulting from savings associated
with avoided repeat hospitalization after the
implantation of a CRT system.
In the light of the current uncertainties surround-
ing the longer-term effects of CRT, a model
approach is the strategy of choice because it offers
Table 5 Main clinical and economic outcomes of  the preliminary base case analysis for Germany
Preliminary results (Base case analysis, 1-year F-U) OPT alone CRT + OPT Difference
Main clinical outcomes (CRT vs. OPT alone)
Relative risk reduction in the total number of  hospital days during the 1-year follow-up period -71%
Relative risk reduction in the number of  death during the 1-year follow-up period -18%
Mean number of  quality-adjusted life-years (QALYs) per “average” patient over 1 year 0.54 0.70 0.16
Cost comparison
Average cost of  successful CRT implantation/patient/year* — €7,220 +€7,220
Average cost of  hospitalization/patient/year† €3,180 €1,680 –€1,500
Average cost of  drug treatment/patient/year‡ €700 €780 +€80
Average cost of  follow-up outpatient care/patient/year‡ €330 €410 +€80
Total direct medical costs/patient/year €4,210 €10,090 +€5,880
Cost-utility ratio (CRT vs. OPT alone)
Incremental cost per QALY gained €36,600
*Failed CRT implantation attempts and procedural death are taken into account for the computation of  this average.
†The costs of  peri-procedural complications are contained in the average amount for the CRT group.
‡These cost values are based on the surviving population.
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the required ﬂexibility to explore the potential
beneﬁts of this new technology in dependence of
varying basic assumptions. With regard to our
explorative German economic appraisal of
CRT + OPT versus OPT alone, the predicted ﬁnd-
ings must be treated with caution. The base-case
evaluation is founded on various estimates for clin-
ical and economic model variables, which all inﬂu-
ence the analysis outcomes. To explore whether the
base case ﬁndings nevertheless can serve as indica-
tor of the economic value of biventricular pacing we
conducted a worst and best case scenario. Over a 1-
year follow-up period CRT can offset a substantial
part of its upfront cost through a signiﬁcant reduc-
tion in hospital readmissions during the follow-up
period. Moreover, the sensitivity analyses showed
that the cost-utility of CRT remains favorable even
under worst case assumptions when compared with
other accepted medical interventions. This con-
clusion is based on the predicted cost per QALY
ranging between €52,100 and €22,400 (base case:
€36,600), which all are below or similar to the
equivalent in euros of the widely used threshold
level of $US50,000 or English £30,000 considered
to characterize cost-effective interventions. There
are other accepted health interventions, for exam-
ple, hemodialysis or treatment of high cholesterol
that have less favorable cost-utility ratios.
We would like to emphasize that our illustrative
ﬁndings are substantially more conservative than
results obtained from  three  economic  studies  with
a pre–post design, which all showed evidence that
CRT may even be cost saving within 1 year
[21,27,34]. All of these studies, however, used
clearly more favorable data regarding reduction of
hospitalization than those reported in the available
two randomized comparative landmark CRT trials
[19,23]. One may therefore argue that the favorable
effect of CRT on hospital admissions under real-life
conditions is more pronounced than under the arti-
ﬁcial setting of randomized clinical trials. In any
case, it can be expected that the cost-utility ratio of
CRT will improve further when analysis periods
exceeding 1 year are considered, because the reduc-
tion in hospitalizations attributable to biventricular
pacing are sustainable according to new ﬁndings
[23,37].
Besides these favorable effects on the quality of
life and hospitalization rate attributable to the
implantation of a CRT system, reliable evidence is
also accumulating that biventricular pacing may
notably decrease mortality in patients experiencing
HF. Data from the COMPANION trial, which com-
pares the effects of three treatments for patients
with advanced HF (OPT, CRT + OPT, and a CRT
device combined with an integrated deﬁbrillator +
OPT), indicate that CRT is associated with a mar-
ginally signiﬁcant reduction in all-cause mortality
over a follow-up period of up to 3 years in patients
with moderate to severe HF [23]. These beneﬁts
may all lead to an increased use of these devices in
the future. Nevertheless, more sensitive and speciﬁc
screening will be required to improve the selection
of patients who will beneﬁt most of this technology
because of the substantial upfront cost of the inter-
vention. Our model may help to generate crucial
data that can improve the decision-making process.
But additional clinical and more importantly eco-
nomic data are needed to enhance the reliability of
the current model results.
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